<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Fulcrum Therapeutics, Inc. — News on 6ix</title>
    <link>https://6ix.com/company/fulcrum-therapeutics-inc</link>
    <description>Latest news and press releases for Fulcrum Therapeutics, Inc. on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Mon, 27 Apr 2026 11:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/fulcrum-therapeutics-inc" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835740b78dffbe2df0f63d1.webp</url>
      <title>Fulcrum Therapeutics, Inc.</title>
      <link>https://6ix.com/company/fulcrum-therapeutics-inc</link>
    </image>
    <item>
      <title>Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2026</title>
      <link>https://6ix.com/company/fulcrum-therapeutics-inc/news/fulcrum-therapeutics-announces-recent-business-highlights-and-financial-results-for-first-quarter-2026</link>
      <guid isPermaLink="true">https://6ix.com/company/fulcrum-therapeutics-inc/news/fulcrum-therapeutics-announces-recent-business-highlights-and-financial-results-for-first-quarter-2026</guid>
      <pubDate>Mon, 27 Apr 2026 11:00:00 GMT</pubDate>
      <description>― Presented positive clinical data for pociredir, demonstrating robust and rapid fetal hemoglobin (HbF) induction, improvements in markers of hemolysis and anemia, and encouraging trends in vaso-occlusive crisis (VOC) reduction ― ― Fulcrum plans to initiate a potential registration-enabling trial in the second half of 2026 ― ― Dosed first patient in an open-label, long-term dosing trial evaluating the long-term safety and durability of response to pociredir in participants previously enrolled in</description>
    </item>
    <item>
      <title>Fulcrum Therapeutics Appoints Josh Lehrer to its Board of Directors</title>
      <link>https://6ix.com/company/fulcrum-therapeutics-inc/news/fulcrum-therapeutics-appoints-josh-lehrer-to-its-board-of-directors</link>
      <guid isPermaLink="true">https://6ix.com/company/fulcrum-therapeutics-inc/news/fulcrum-therapeutics-appoints-josh-lehrer-to-its-board-of-directors</guid>
      <pubDate>Mon, 27 Apr 2026 10:55:00 GMT</pubDate>
      <description>CAMBRIDGE, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (NASDAQ: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules that improve the lives of patients with rare hematological disorders, today announced that Josh Lehrer, M.D., M.Phil., FACC, has been appointed to its Board of Directors as an independent director. Dr. Lehrer is a physician-scientist and biotechnology executive with more than two decades of clinical development</description>
    </item>
    <item>
      <title>Fulcrum Therapeutics to Host First Quarter 2026 Financial Results Conference Call and Webcast on Monday, April 27, 2026, at 8:00 a.m. ET</title>
      <link>https://6ix.com/company/fulcrum-therapeutics-inc/news/fulcrum-therapeutics-to-host-first-quarter-2026-financial-results-conference-call-and-webcast-on-monday-april-27-2026-at-800-am-et</link>
      <guid isPermaLink="true">https://6ix.com/company/fulcrum-therapeutics-inc/news/fulcrum-therapeutics-to-host-first-quarter-2026-financial-results-conference-call-and-webcast-on-monday-april-27-2026-at-800-am-et</guid>
      <pubDate>Mon, 20 Apr 2026 12:00:00 GMT</pubDate>
      <description>CAMBRIDGE, Mass., April 20, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that its first quarter 2026 financial results will be released on Monday, April 27, 2026, before the U.S. financial markets open. Management will host a conference call and webcast at 8:00 a.m. ET to discuss the resul</description>
    </item>
    <item>
      <title>MedicAlert Foundation, Sickle Cell Disease Association of America, Inc. (SCDAA), and Fulcrum Therapeutics Partner to Accelerate Emergency Department Access to Critical Care Information for People Living with Sickle Cell Disease</title>
      <link>https://6ix.com/company/fulcrum-therapeutics-inc/news/medicalert-foundation-sickle-cell-disease-association-of-america-inc-scdaa-and-fulcrum-therapeutics-partner-to-accelerate-emergency-department-access-to-critical-care-information-for-people-living-with-sickle-cell-disease</link>
      <guid isPermaLink="true">https://6ix.com/company/fulcrum-therapeutics-inc/news/medicalert-foundation-sickle-cell-disease-association-of-america-inc-scdaa-and-fulcrum-therapeutics-partner-to-accelerate-emergency-department-access-to-critical-care-information-for-people-living-with-sickle-cell-disease</guid>
      <pubDate>Thu, 19 Mar 2026 12:00:00 GMT</pubDate>
      <description>Three-year collaboration is aimed at enhancing a key aspect of sickle cell management: expediting care during a pain crisisCAMBRIDGE, Mass., March 19, 2026 (GLOBE NEWSWIRE) -- MedicAlert Foundation, the leading nonprofit providing medical IDs and emergency medical information services, Sickle Cell Disease Association of America, Inc., (SCDAA), the national voice for people affected by sickle cell disease and their caregivers, and Fulcrum Therapeutics Inc. (Fulcrum) (Nasdaq: FULC), a leader in ad</description>
    </item>
    <item>
      <title>Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results  for Fourth Quarter and Full Year 2025</title>
      <link>https://6ix.com/company/fulcrum-therapeutics-inc/news/fulcrum-therapeutics-announces-recent-business-highlights-and-financial-results-for-fourth-quarter-and-full-year-2025</link>
      <guid isPermaLink="true">https://6ix.com/company/fulcrum-therapeutics-inc/news/fulcrum-therapeutics-announces-recent-business-highlights-and-financial-results-for-fourth-quarter-and-full-year-2025</guid>
      <pubDate>Tue, 24 Feb 2026 12:01:00 GMT</pubDate>
      <description>― Announced positive 12-week results from the 20 mg dose cohort of the Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD) ― ― 20 mg cohort demonstrated rapid and robust fetal hemoglobin (HbF) induction, with mean absolute HbF increasing by 12.2% from a baseline of 7.1% to 19.3% at Week 12, improvements in markers of hemolysis and anemia, and encouraging trends in vaso-occlusive crisis (VOC) reduction ― ― Fulcrum plans to initiate a potential registration-enabling trial in the secon</description>
    </item>
    <item>
      <title>Fulcrum Therapeutics Announces Positive 12-Week Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease</title>
      <link>https://6ix.com/company/fulcrum-therapeutics-inc/news/fulcrum-therapeutics-announces-positive-12-week-results-from-the-20-mg-dose-cohort-of-the-phase-1b-pioneer-trial-of-pociredir-in-sickle-cell-disease</link>
      <guid isPermaLink="true">https://6ix.com/company/fulcrum-therapeutics-inc/news/fulcrum-therapeutics-announces-positive-12-week-results-from-the-20-mg-dose-cohort-of-the-phase-1b-pioneer-trial-of-pociredir-in-sickle-cell-disease</guid>
      <pubDate>Tue, 24 Feb 2026 05:00:00 GMT</pubDate>
      <description>― Mean absolute fetal hemoglobin (HbF) increased by 12.2% (from 7.1% to 19.3%) at Week 12 (n=12), representing a rapid, robust, and clinically relevant</description>
    </item>
    <item>
      <title>Fulcrum Therapeutics to Present 12-Week Data from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease</title>
      <link>https://6ix.com/company/fulcrum-therapeutics-inc/news/fulcrum-therapeutics-to-present-12-week-data-from-the-20-mg-dose-cohort-of-the-phase-1b-pioneer-trial-of-pociredir-in-sickle-cell-disease</link>
      <guid isPermaLink="true">https://6ix.com/company/fulcrum-therapeutics-inc/news/fulcrum-therapeutics-to-present-12-week-data-from-the-20-mg-dose-cohort-of-the-phase-1b-pioneer-trial-of-pociredir-in-sickle-cell-disease</guid>
      <pubDate>Tue, 17 Feb 2026 13:00:00 GMT</pubDate>
      <description>CAMBRIDGE, Mass., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, will host a conference call and webcast on Tuesday, February 24, 2026 beginning at 8:00 a.m. ET to present 12-week results from the 20 mg dose cohort of the Phase 1b PIONEER trial of pociredir in sickle cell disease. Members of Fulcrum mana</description>
    </item>
    <item>
      <title>Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)</title>
      <link>https://6ix.com/company/fulcrum-therapeutics-inc/news/fulcrum-therapeutics-reports-inducement-grants-213000803</link>
      <guid isPermaLink="true">https://6ix.com/company/fulcrum-therapeutics-inc/news/fulcrum-therapeutics-reports-inducement-grants-213000803</guid>
      <pubDate>Fri, 09 Jan 2026 21:30:00 GMT</pubDate>
      <description>CAMBRIDGE, Mass., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that the company granted non-statutory stock options to three new employees. Fulcrum granted stock options to purchase shares of the company’s common stock pursuant to the company’s 2022 Inducement Stock Incentive Plan, as amended, or</description>
    </item>
    <item>
      <title>Fulcrum Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference</title>
      <link>https://6ix.com/company/fulcrum-therapeutics-inc/news/fulcrum-therapeutics-participate-44th-annual-jp-morgan-healthcare-conference-2026-01</link>
      <guid isPermaLink="true">https://6ix.com/company/fulcrum-therapeutics-inc/news/fulcrum-therapeutics-participate-44th-annual-jp-morgan-healthcare-conference-2026-01</guid>
      <pubDate>Wed, 07 Jan 2026 05:00:00 GMT</pubDate>
      <description>CAMBRIDGE, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused</description>
    </item>
    <item>
      <title>Fulcrum Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering of Common Stock and Pre-Funded Warrants</title>
      <link>https://6ix.com/company/fulcrum-therapeutics-inc/news/fulcrum-therapeutics-announces-pricing-upsized-1750-million-public-offering-common</link>
      <guid isPermaLink="true">https://6ix.com/company/fulcrum-therapeutics-inc/news/fulcrum-therapeutics-announces-pricing-upsized-1750-million-public-offering-common</guid>
      <pubDate>Wed, 10 Dec 2025 05:00:00 GMT</pubDate>
      <description>CAMBRIDGE, Mass., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (“Fulcrum”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company</description>
    </item>
    <item>
      <title>Fulcrum Therapeutics Announces Proposed $150.0 Million Public Offering of Common Stock</title>
      <link>https://6ix.com/company/fulcrum-therapeutics-inc/news/fulcrum-therapeutics-announces-proposed-1500-million-public-offering-common-stock</link>
      <guid isPermaLink="true">https://6ix.com/company/fulcrum-therapeutics-inc/news/fulcrum-therapeutics-announces-proposed-1500-million-public-offering-common-stock</guid>
      <pubDate>Mon, 08 Dec 2025 05:00:00 GMT</pubDate>
      <description>CAMBRIDGE, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (“Fulcrum”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused</description>
    </item>
    <item>
      <title>Fulcrum Therapeutics Announces Positive Initial Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting</title>
      <link>https://6ix.com/company/fulcrum-therapeutics-inc/news/fulcrum-therapeutics-announces-positive-initial-results-20-mg-dose-cohort-phase-1b</link>
      <guid isPermaLink="true">https://6ix.com/company/fulcrum-therapeutics-inc/news/fulcrum-therapeutics-announces-positive-initial-results-20-mg-dose-cohort-phase-1b</guid>
      <pubDate>Sat, 06 Dec 2025 05:00:00 GMT</pubDate>
      <description>― Clear dose-response observed, with a robust and clinically meaningful fetal hemoglobin (HbF) induction at the Week 6 timepoint (n=12): mean absolute HbF in</description>
    </item>
    <item>
      <title>Fulcrum Therapeutics to Host Investor Event to Review New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease on December 7, 2025</title>
      <link>https://6ix.com/company/fulcrum-therapeutics-inc/news/fulcrum-therapeutics-host-investor-event-review-new-clinical-data-pioneer-trial</link>
      <guid isPermaLink="true">https://6ix.com/company/fulcrum-therapeutics-inc/news/fulcrum-therapeutics-host-investor-event-review-new-clinical-data-pioneer-trial</guid>
      <pubDate>Tue, 02 Dec 2025 05:00:00 GMT</pubDate>
      <description>CAMBRIDGE, Mass., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on</description>
    </item>
    <item>
      <title>Fulcrum Therapeutics to Present New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting</title>
      <link>https://6ix.com/company/fulcrum-therapeutics-inc/news/fulcrum-therapeutics-present-new-clinical-data-pioneer-trial-pociredir-sickle-cell</link>
      <guid isPermaLink="true">https://6ix.com/company/fulcrum-therapeutics-inc/news/fulcrum-therapeutics-present-new-clinical-data-pioneer-trial-pociredir-sickle-cell</guid>
      <pubDate>Mon, 03 Nov 2025 05:00:00 GMT</pubDate>
      <description>― Pociredir Phase 1b PIONEER Trial Data in Sickle Cell Disease to be Presented and Published, Including 12 mg and 20 mg Cohorts ― ― Live and Webcast Investor</description>
    </item>
    <item>
      <title>Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2025</title>
      <link>https://6ix.com/company/fulcrum-therapeutics-inc/news/fulcrum-therapeutics-announces-recent-business-highlights-and-financial-results-third</link>
      <guid isPermaLink="true">https://6ix.com/company/fulcrum-therapeutics-inc/news/fulcrum-therapeutics-announces-recent-business-highlights-and-financial-results-third</guid>
      <pubDate>Wed, 29 Oct 2025 04:00:00 GMT</pubDate>
      <description>― Patient enrollment and site activation progressing in Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD) ― ― Ended the third quarter of 2024</description>
    </item>
    <item>
      <title>Fulcrum Therapeutics to Host Third Quarter 2025 Financial Results Conference Call and Webcast on Wednesday, October 29, 2025, at 8:00 a.m. ET</title>
      <link>https://6ix.com/company/fulcrum-therapeutics-inc/news/fulcrum-therapeutics-host-third-quarter-2025-financial-results-conference-call-and</link>
      <guid isPermaLink="true">https://6ix.com/company/fulcrum-therapeutics-inc/news/fulcrum-therapeutics-host-third-quarter-2025-financial-results-conference-call-and</guid>
      <pubDate>Wed, 22 Oct 2025 04:00:00 GMT</pubDate>
      <description>CAMBRIDGE, Mass., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company</description>
    </item>
    <item>
      <title>Fulcrum Therapeutics to Present Preclinical Data for EED Inhibitor FTX-6274 at European Society for Medical Oncology (ESMO) Congress 2025</title>
      <link>https://6ix.com/company/fulcrum-therapeutics-inc/news/fulcrum-therapeutics-present-preclinical-data-eed-inhibitor-ftx-6274-european-society</link>
      <guid isPermaLink="true">https://6ix.com/company/fulcrum-therapeutics-inc/news/fulcrum-therapeutics-present-preclinical-data-eed-inhibitor-ftx-6274-european-society</guid>
      <pubDate>Tue, 14 Oct 2025 04:00:00 GMT</pubDate>
      <description>― Preclinical data of FTX-6274 suggests potential for the treatment of castration resistant prostate cancer ― CAMBRIDGE, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE)</description>
    </item>
    <item>
      <title>Fulcrum Therapeutics to Present at Upcoming Investor Meetings</title>
      <link>https://6ix.com/company/fulcrum-therapeutics-inc/news/fulcrum-therapeutics-present-upcoming-investor-meetings-2025-08-26</link>
      <guid isPermaLink="true">https://6ix.com/company/fulcrum-therapeutics-inc/news/fulcrum-therapeutics-present-upcoming-investor-meetings-2025-08-26</guid>
      <pubDate>Tue, 26 Aug 2025 04:00:00 GMT</pubDate>
      <description>CAMBRIDGE, Mass., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company</description>
    </item>
    <item>
      <title>Fulcrum Therapeutics Announces Results from the 12 mg Dose Cohort of the  Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease</title>
      <link>https://6ix.com/company/fulcrum-therapeutics-inc/news/fulcrum-therapeutics-announces-results-12-104500311</link>
      <guid isPermaLink="true">https://6ix.com/company/fulcrum-therapeutics-inc/news/fulcrum-therapeutics-announces-results-12-104500311</guid>
      <pubDate>Tue, 29 Jul 2025 10:45:00 GMT</pubDate>
      <description>― Robust and clinically meaningful absolute mean fetal hemoglobin (HbF) induction of 8.6% from baseline at 12 weeks of treatment; 7 of 16 patients achieved absolute HbF levels greater than 20% ― ― Evidence of pan-cellular induction of HbF based on an increase in F-cells (red blood cells containing HbF) from a mean of 34% at baseline to 67% at 12 weeks of treatment ― ― Meaningful improvements in key markers of hemolysis coupled with a 0.9 g/dL mean increase in total hemoglobin (Hb) ― ― Encouragin</description>
    </item>
    <item>
      <title>Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2025</title>
      <link>https://6ix.com/company/fulcrum-therapeutics-inc/news/fulcrum-therapeutics-announces-recent-business-highlights-and-financial-results</link>
      <guid isPermaLink="true">https://6ix.com/company/fulcrum-therapeutics-inc/news/fulcrum-therapeutics-announces-recent-business-highlights-and-financial-results</guid>
      <pubDate>Tue, 29 Jul 2025 04:00:00 GMT</pubDate>
      <description>― On track to report topline data for Phase 3 REACH trial of losmapimod in facioscapulohumeral muscular dystrophy (FSHD) by the end of October 2024 ― ―</description>
    </item>
  </channel>
</rss>